Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel application of human-derived ribosomal protein L22 in anti-cancer anti-tumor medicines

A ribosomal protein and anti-tumor drug technology, applied in anti-tumor drugs, drug combinations, peptide/protein components, etc., can solve problems such as RPL22 that has not been used, achieve good tissue compatibility, reduce toxic side effects, and reduce usage effect of dosage

Inactive Publication Date: 2017-05-31
杨明夏
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although it is mentioned in the article that RPL22 can be used to characterize cancer, we know that characterizing cancer and treating cancer are two different things. The existing technology has not used RPL22 as an anti-cancer or anti-tumor drug.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of human-derived ribosomal protein L22 in anti-cancer anti-tumor medicines
  • Novel application of human-derived ribosomal protein L22 in anti-cancer anti-tumor medicines
  • Novel application of human-derived ribosomal protein L22 in anti-cancer anti-tumor medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Experiment of human ribosomal protein RPL22 in proliferation of lung cancer cells

[0031] The experimental process is as follows:

[0032] 1. Plant lung cancer cells in a 96-well plate, and make three replicate wells for each group. The medium in each well is 100 μL, and the number of lung cancer cells is 5,000. Put the lung cancer cells in a 37°C incubator, 5% CO 2 , cultivated under saturated humidity conditions.

[0033] 2. The initial concentration of the drug mother solution is 0.25μg / μl, and the drug is diluted according to the appropriate dilution method, so that the drug concentration in the culture well is 1 / 50, 1 / 100, 1 / 200, 1 / 400, 1 / 600, 1 / 800, 1 / 1000, medium for the control group; after 48 hours of post-treatment, absorb excess medium, then add 80µl fresh medium, add 20µl CCK8, 37°C, 5% CO 2 , cultivated under saturated humidity conditions for 2 hours, and measured the OD value of each well in an enzyme-linked immunosorbent detector with dual w...

Embodiment 2

[0036] Example 2 Experiment of anti-tumor therapy of human ribosomal protein RPL22 in tumor-bearing mice.

[0037] Using cell culture medium as a diluent, human lung cancer cell lines A549 and Ltep-a-2 were planted subcutaneously in nude mice to construct a lung cancer implantation tumor model, and the RPL22 protein was diluted by the method of doubling dilution. The implanted tumors in nude mice were treated by local injection. The human ribosomal protein RPL22 used in the experiment was purchased from PROSPEC, and the nude mice were purchased from Changzhou Cavens Experimental Animal Company. Male mice aged 6-8 weeks were used.

[0038] The experimental process is as follows:

[0039] 1. The human lung cancer cell lines A549 and Ltep-a-2 were expanded and cultured, and the tumor cells in the logarithmic growth phase were used for the tumor-bearing experiment.

[0040] 2. Charge 1×10 6 For cells in logarithmic growth phase, wash tumor cells once with 1×PBS.

[0041] 3. Ad...

Embodiment 3

[0050] Example 3 Human-derived ribosomal protein RPL22 cooperates with cisplatin DDP to inhibit the proliferation of lung cancer cells

[0051] 1. Plant lung cancer cells in a 96-well plate, and make three replicate wells for each group. The medium in each well is 100 μL, and the number of lung cancer cells is 5,000. Put the lung cancer cells in a 37°C incubator, 5% CO 2 , cultivated under saturated humidity conditions.

[0052] 2. According to the drug experiment, the IC50 of DDP on two kinds of lung cancer cells was measured as 10 μM ( image 3 ), and on this basis, drug synergy experiments were carried out. The initial concentration of the RPL22 protein drug mother solution is 0.25μg / μl, and the RPL22 drug concentration when the volume in the culture well is 100μl is 1 / 100 of the mother solution, that is, the final concentration is 0.025ng / μl; the cells are divided into groups: DDP (10uM), RPL22, RPL22+DDP(1.25uM), RPL22+DDP(2.5uM), RPL22+DDP(5uM); After 48 hours of post-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of biomedicines, and particularly relates to application of complete sequence protein of a human-derived ribosomal protein L22 (RPL22) in anti-cancer anti-tumor medicines. For the complete sequence protein of recombinant human-derived RPL22 in medicines for treating non-small cell lung cancer or anti-tumor medicines, the sequence of the RPL22 is as shown in a sequence 1. The recombinant human-derived RPL22 can be used as an endogenous casein kinase inhibitor to achieve the anti-cancer activity, and has an effect of individually inhibiting cancer cell activity in the field of non-small cell lung cancer inhibition. The protein is a human own endogenous protein, has good biological safety, and can be combined with other anti-cancer medicines on the premise that relatively strong anti-cancer activity is ensured so as to reduce dosage of other anti-cancer medicines and toxic and side effects of other anti-cancer medicines.

Description

technical field [0001] The invention relates to the technical field of biopharmaceuticals, in particular to a new application of a human-derived ribosomal protein (Ribosomalprotein L22, RPL22) full-sequence protein as an anticancer and antitumor drug. Background technique [0002] Statistics show that lung cancer has become the leading cause of human death due to cancer; and in my country, the incidence and mortality of lung cancer also rank first among all types of cancer. Due to the complex etiology and molecular biological mechanism of its pathogenesis have not been fully elucidated, the clinical treatment effect is not good; finding effective treatment methods is an urgent problem to be solved in the current treatment of non-small cell lung cancer. Ribosomal protein (RP) is a very important regulatory gene in the process of cell growth, which may directly affect the process of cell proliferation and differentiation, and the mechanism of action is different in cells from ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P35/00A61K33/24
CPCA61K33/24A61K38/1709A61K2300/00
Inventor 杨明夏
Owner 杨明夏
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com